Royalty Pharma (RPRX) Times Interest Earned (2019 - 2026)
Royalty Pharma (RPRX) posted Times Interest Earned of $2.52 for Q1 2026, down 75.33% sequentially from $10.21 in Q4 2025, and down 13.97% YoY from $2.93 in Q1 2025.
Royalty Pharma (RPRX) Times Interest Earned (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Times Interest Earned for 8 years, with the latest figure at $2.52 in Q1 2026.
- Quarterly Times Interest Earned fell 13.97% year-over-year to $2.52 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 (down 31.78% YoY) and the FY2025 annual result came in at $5.07, down 11.56% from the prior year.
- Times Interest Earned slipped to $2.52 in Q1 2026 per RPRX's latest filing, from $10.21 in the prior quarter.
- Over five years, Times Interest Earned peaked at $20.96 in Q4 2023 and troughed at -$1997.3 in Q4 2024.
- A 5-year average of -$157.44 and a median of $1.31 in 2024 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2022 and 2025: Times Interest Earned slumped 22389.86% in 2022, then surged 737.19% in 2025.
- Over 5 years, Times Interest Earned stood at -$727.99 in 2022, then jumped by 102.88% to $20.96 in 2023, then sank by 9627.47% to -$1997.3 in 2024, then jumped by 100.51% to $10.21 in 2025, then slumped by 75.33% to $2.52 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered $2.52, $10.21, and $5.37 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -55.73 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.61 |
| Mar 31, 2026 | 2.52 |
| Dec 31, 2025 | 10.21 |
| Sep 30, 2025 | 5.37 |
| Jun 30, 2025 | 1.18 |
| Mar 31, 2025 | 2.93 |
| Dec 31, 2024 | -1,997.31 |
| Sep 30, 2024 | 3.82 |
| Jun 30, 2024 | 1.31 |
| Mar 31, 2024 | -0.46 |
| Dec 31, 2023 | 20.96 |
| Sep 30, 2023 | 0.90 |
| Jun 30, 2023 | 1.43 |
| Mar 31, 2023 | 2.68 |
| Dec 31, 2022 | -727.99 |
| Sep 30, 2022 | -1.02 |
| Jun 30, 2022 | -1.95 |
| Mar 31, 2022 | -1.10 |
| Dec 31, 2021 | 3.27 |
| Sep 30, 2021 | -1.45 |